Challenges to Increase Access to Vaccines in the Americas

Dr. Jarbas Barbosa
Assistant Director
Pan American Health Organization
The Region: Good news

The path of disease elimination
Number of unvaccinated children with DPT3 per year, selected countries and Region, 2010-2018

Antigens introduced in national immunization schedules

Rotavirus:
22 countries and territories

Legend:
- Introduced
- Partial
- Haven’t introduced

PCV:
37 countries and territories

Legend:
- Introduced
- Haven’t introduced
The Region: Challenges

Rapid Urbanization
80%
56 (2010)

Natural disasters
- 6.6 quake hits Mexico:
  Peru: Deadly floods and landslides hit Huancavelica
- Deadly landslides hit Colombia for 2nd time in 2 weeks
- Saint Martin Is Making a Comeback After Hurricane Irma
- Guatemala’s erupting Volcan de Fuego triggers evacuations

Political context
- ¿Se muere el sueño de la paz?
  EL PAÍS
- Deaths reported as protests against President turn violent
  24
- The New York Times
  Nueve vicios de las elecciones latinoamericanas en un solo ejemplo
  CNN

Equity
CEPAL: Pese a avances recientes, América Latina sigue siendo la región más desigual del mundo

https://www.cepal.org/es/publicaciones/44395-panorama-social-américa-latina-2018
Key Components for Access to Vaccines

Accurate demand planning

Timely availability of funds

Efficient procurement mechanisms

Sustainable/affordable supply market

ACCESS
The PAHO Revolving Fund

41 countries and territories

25 million people are protected annually with at least one vaccine procured through the PAHO Revolving Fund.
A Snapshot of Developing Country Manufacturers
PAHO/WHO’s Program of Technical Cooperation for National Immunization Programs: Evidence-based Decision Making

Disease burden
Vaccine characteristics
  • Immunogenicity
  • Efficacy/effectiveness
  • Waning
  • Serotype coverage
  • Dosing
Safety, post-marketing AE
Cost-effectiveness

Immunization Program Tools:
  • Tech. Advisory Group (TAG)
  • ProVac (cost-effectiveness)
  • Strengthening NITAGs
  • Systematic Reviews
  • Vaccine Legislation
  • National Plans of Action
  • Demand generation

Demand Forecasting (PAHO 173)
Quality Supply (WHO PQ)
Timely Deliveries
Logistic issues
Financing, Sustainability Partnerships

PAHO Revolving Fund

Accepability
Risk perception
Political will
Equity

Strengthening Vaccine Production Capacities for National Laboratories, 2019

Update to landscape analysis - Diagnosis of existing manufacturing capabilities, national products, plans processes and alliances.

Identifying opportunities for interaction with laboratories impacting their production plans and procedures.

Outline broader PAHO strategy to ensure commitments compliance and regional solidarity.

Based on principles of transparency, avoid conflicts of interest while proposing a corporate strategy for consideration.
Challenges for the supply

- Stagnant/decreasing coverage rates
- Global supply constraints for critical vaccines like IPV, Measles Containing Vaccines, Yellow Fever, HPV
- Concentrated (monopolistic) supply market for some products
- High prices for new vaccines
- Forecasting accuracy, programme planning and stock management
- Suboptimal production capacities and product portfolio for the national manufacturers in the Latin America
PAHO’s involvement over the years to support national production capacities

PAHO has been providing guidance for increasing technical and regulatory capacities. There are selected publications by PAHO experts.

The PAHO Executive Committee Meeting in 1994 called on Member Countries for the promotion of vaccine production, including public and private producing laboratories (SIREVA).

Implementation of strategies for DTP manufacturing improvement, Penta Latina development, etc.

Promotion of partnering for vaccine emerging markets and attention to vaccine demand and chain supply.

Encouraging South-South cooperation.

PAHO's involvement over the years to support national production capacities

Executive committee of the regional directors

Working party of the regional directors

PAHO's involvement over the years to support national production capacities

World Health Organization

Regional System for Vaccine Development in Latin America and the Caribbean (SIREVA)

Biologicus

Review

Public vaccine manufacturing capacity in the Latin American and Caribbean region: Current status and perspectives

Maria de las Angeles Carvajal, Daniel Cardona, James Fitzgerald, Jose Luis Bribiesco

Abstract

PAHO's involvement over the years to support national production capacities
**PAHO RF’s Evolving Vaccine Market Trends: Role of IFPMA* and DCVMN** Suppliers, 2011-18

### Additional saving as result of buying from DCVMN (Ex. Penta $3.50 - $1.00)

- **Result from negotiations with two HPV suppliers:** US$1.5 millions in savings*
- **Result from negotiations with two PCV suppliers:** US$10.9 millions in savings**

* For participating countries from 2017-2018
** For participating countries from 2017-2018

* IFPMA: International Federation of Pharmaceutical Manufacturers
** DCVMN: Developing Countries Vaccine Manufacturers Network
Way Forward

1. Enhanced coordination on **Demand Planning**
   - Forecasting accuracy
   - Outbreak risk / scenario analysis
   - Joint demand planning with self-procuring countries

2. Technical Support to **National Regulatory Authorities**

3. Technical Support to national manufacturing capacities
   - Diagnostic on capacities
   - South-south collaboration
   - Promoting public-private partnerships and sustainable business models

4. Strengthening collaborations with international partners on vaccine access
   - WHO’s EYE initiative
   - Measles Rubella Initiative (MRI)
   - GPEI
Thank you!